Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIIb, multi-center, stratified, open-label study to evaluate the immunogenicity, steady state trough level, and safety of subcutaneous abatacept (BMS-188667) in subjects with rheumatoid arthritis administered with or without background methotrexate

Next Previous
X
Search
Trial Profile

A phase IIIb, multi-center, stratified, open-label study to evaluate the immunogenicity, steady state trough level, and safety of subcutaneous abatacept (BMS-188667) in subjects with rheumatoid arthritis administered with or without background methotrexate

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ACCOMPANY
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 07 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Results presented at 2009 Annual Scientific Meeting of the American College of Rheumatology, according to a BristolMyers Squibb media release.
    • 04 Sep 2009 Planned end date changed from 1 Oct 2008 to 1 Jan 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top